16.12
price down icon3.47%   -0.58
 
loading
Schlusskurs vom Vortag:
$16.70
Offen:
$16.58
24-Stunden-Volumen:
1.88M
Relative Volume:
1.42
Marktkapitalisierung:
$2.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.1527
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+8.77%
1M Leistung:
+0.19%
6M Leistung:
-12.82%
1J Leistung:
-47.47%
1-Tages-Spanne:
Value
$16.07
$16.74
1-Wochen-Bereich:
Value
$14.47
$17.06
52-Wochen-Spanne:
Value
$12.72
$34.47

Immunovant Inc Stock (IMVT) Company Profile

Name
Firmenname
Immunovant Inc
Name
Telefon
917-580-3099
Name
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Name
Mitarbeiter
362
Name
Twitter
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
IMVT's Discussions on Twitter

Vergleichen Sie IMVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMVT
Immunovant Inc
16.12 2.63B 0 -382.71M -325.64M -2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.93 102.81B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
453.54 58.59B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.22 61.25B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
733.66 43.23B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.73 36.53B 3.81B -644.79M -669.77M -6.24

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Neutral
2025-03-03 Eingeleitet Jefferies Hold
2025-01-03 Herabstufung Wolfe Research Outperform → Peer Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-09 Bestätigt Oppenheimer Outperform
2024-03-28 Eingeleitet Oppenheimer Outperform
2024-03-13 Eingeleitet Goldman Buy
2024-02-20 Eingeleitet JP Morgan Overweight
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-13 Hochstufung UBS Neutral → Buy
2023-09-26 Hochstufung Raymond James Mkt Perform → Outperform
2023-05-01 Eingeleitet BofA Securities Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-31 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Stifel Buy
2023-02-15 Eingeleitet Cantor Fitzgerald Overweight
2023-02-13 Hochstufung Guggenheim Neutral → Buy
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-09-26 Herabstufung UBS Buy → Neutral
2021-12-08 Eingeleitet Wells Fargo Equal Weight
2021-08-03 Herabstufung Robert W. Baird Outperform → Neutral
2021-08-02 Herabstufung Credit Suisse Neutral → Underperform
2021-06-01 Herabstufung Guggenheim Buy → Neutral
2021-06-01 Herabstufung Stifel Buy → Hold
2020-10-28 Eingeleitet UBS Buy
2020-10-12 Eingeleitet Guggenheim Buy
2020-10-08 Eingeleitet Stifel Buy
2020-10-02 Eingeleitet Credit Suisse Outperform
2020-08-26 Bestätigt H.C. Wainwright Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-07-29 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet SVB Leerink Outperform
Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

pulisher
02:58 AM

Earnings visualization tools for Immunovant Inc.Market Activity Summary & Consistent Income Trade Recommendations - Newser

02:58 AM
pulisher
Sep 04, 2025

Is Immunovant Inc. trending in predictive chart modelsJuly 2025 Levels & Weekly Return Optimization Alerts - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Immunovant reports promising remission data for Graves’ disease therapy By Investing.com - Investing.com Australia

Sep 04, 2025
pulisher
Sep 04, 2025

What is Immunovant Inc.’s book value per shareJuly 2025 Update & Daily Volume Surge Trade Alerts - khodrobank.com

Sep 04, 2025
pulisher
Sep 04, 2025

Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech

Sep 04, 2025
pulisher
Sep 04, 2025

Immunovant’s Batoclimab: A Game-Changer in the Evolving Graves’ Disease Market - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - TradingView

Sep 04, 2025
pulisher
Sep 04, 2025

Momentum divergence signals in Immunovant Inc. chart2025 Buyback Activity & AI Enhanced Trading Alerts - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Is Immunovant Inc. a strong growth stockMarket Volume Summary & Consistent Income Trade Recommendations - khodrobank.com

Sep 04, 2025
pulisher
Sep 04, 2025

What machine learning models say about Immunovant Inc.2025 Market Trends & Verified Entry Point Detection - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Immunovant stock rises as Oppenheimer reiterates Outperform on Graves’ data - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

Real time social sentiment graph for Immunovant Inc.Entry Point & Long-Term Safe Return Strategies - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

What institutional flow reveals about Immunovant Inc.Market Trend Report & AI Optimized Trading Strategy Guides - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Combining price and volume data for Immunovant Inc.July 2025 Outlook & Reliable Intraday Trade Plans - Newser

Sep 04, 2025
pulisher
Sep 03, 2025

Why Immunovant Stock Blasted Higher Today - AOL.com

Sep 03, 2025
pulisher
Sep 03, 2025

Can momentum traders help lift Immunovant Inc.Portfolio Return Report & Verified Chart Pattern Trade Signals - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Why Immunovant Stock Blasted Higher Today - The Motley Fool

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Reports 'Encouraging' Data on Graves' Disease Treatment; Shares Rise - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

What to expect from Immunovant Inc. in the next 30 daysQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Data for Batoclimab Shows Potential for Treating Uncontrolled Graves' Disease - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Announces Promising Graves’ Disease Study Results - TipRanks

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - The Manila Times

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant reports promising remission data for Graves’ disease therapy - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Reports Promising Six-Month Off-Treatment Data for Batoclimab in Uncontrolled Graves' Disease Patients - Quiver Quantitative

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy - Quiver Quantitative

Sep 03, 2025
pulisher
Sep 03, 2025

80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan

Sep 03, 2025
pulisher
Sep 03, 2025

Using data tools to time your Immunovant Inc. exit2025 Big Picture & Low Risk Entry Point Tips - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Visual analytics tools that track Immunovant Inc. performanceJuly 2025 Sentiment & Community Verified Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Intraday pattern recognizer results for Immunovant Inc.Market Activity Summary & Real-Time Stock Price Movement Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using RSI to spot recovery in Immunovant Inc.M&A Rumor & Consistent Growth Stock Picks - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Volume spikes in Immunovant Inc. stock – what they meanRisk Management & Advanced Technical Signal Analysis - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

How to use a screener to detect Immunovant Inc. breakoutsJuly 2025 Rallies & Stepwise Trade Signal Implementation - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Applying Elliott Wave Theory to Immunovant Inc.July 2025 Update & Verified Momentum Watchlists - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Inc. stock volume spike explainedWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is now a turning point for Immunovant Inc.2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Immunovant Inc. stock entering bullish territoryQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Real time breakdown of Immunovant Inc. stock performanceCPI Data & Fast Gaining Stock Strategy Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

What indicators show strength in Immunovant Inc.Quarterly Earnings Report & Weekly Watchlist for Hot Stocks - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Using economic indicators to assess Immunovant Inc. potentialMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Immunovant Inc. stock outlook for YEARJuly 2025 Review & Fast Gaining Stock Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is Immunovant Inc. stock poised for growthMarket Movement Recap & Free Weekly Watchlist of Top Performers - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Long term hold vs stop loss in Immunovant Inc.Layoff News & Expert Approved Momentum Trade Ideas - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

What’s next for Immunovant Inc. stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Short interest data insights for Immunovant Inc.July 2025 Patterns & Fast Entry and Exit Trade Plans - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Immunovant Inc. stock trend outlook and recovery pathPortfolio Value Summary & Low Volatility Stock Suggestions - Newser

Sep 02, 2025
pulisher
Sep 01, 2025

Should you avoid Immunovant Inc. stock right nowJuly 2025 Update & Advanced Swing Trade Entry Alerts - khodrobank.com

Sep 01, 2025
pulisher
Sep 01, 2025

Regression analysis insights on Immunovant Inc. performanceQuarterly Profit Review & Expert Approved Momentum Ideas - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Published on: 2025-09-01 10:52:28 - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Is Immunovant Inc. a play on infrastructure spendingTrend Reversal & Safe Entry Zone Tips - khodrobank.com

Sep 01, 2025

Finanzdaten der Immunovant Inc-Aktie (IMVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Immunovant Inc-Aktie (IMVT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Geffner Michael
Chief Medical Officer
Jul 23 '25
Sale
18.15
2,385
43,288
221,825
Geffner Michael
Chief Medical Officer
Jul 09 '25
Sale
17.24
1,160
19,998
224,210
Stout Jay S
Chief Technology Officer
Jul 09 '25
Sale
17.24
1,519
26,188
207,724
$85.44
price down icon 1.75%
$27.38
price up icon 1.11%
$23.80
price up icon 1.19%
$103.50
price up icon 3.07%
$142.53
price down icon 0.68%
biotechnology ONC
$318.73
price down icon 5.21%
Kapitalisierung:     |  Volumen (24h):